EQUILLIUM, INC. Revenue Breakdown
No Revenue Breakdown for EQ on this site yet.
- 2024-12-31: Others Not split by product in the filing$41.09M100.00%; Total revenue $41.09M.
- 2023-12-31: Others Not split by product in the filing$36.08M100.00%; Total revenue $36.08M.
- 2022-12-31: Others Not split by product in the filing$15.76M100.00%; Total revenue $15.76M.
Source checked: the stored Revenue Breakdown page for EQ.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2024-12-31 | Not split by product in the filing $41.09M 100.00% | $41.09M |
| 2023-12-31 | Not split by product in the filing $36.08M 100.00% | $36.08M |
| 2022-12-31 | Not split by product in the filing $15.76M 100.00% | $15.76M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2024-12-31 | Not split by product $4.39M 100.00% | $4.39M |
| 2024-09-30 | Not split by product $12.16M 100.00% | $12.16M |
| 2024-06-30 | Not split by product $13.85M 100.00% | $13.85M |
| 2024-03-31 | Not split by product $10.69M 100.00% | $10.69M |
| 2023-12-31 | Not split by product $9.21M 100.00% | $9.21M |
| 2023-09-30 | Not split by product $8.87M 100.00% | $8.87M |
| 2023-06-30 | Not split by product $9.12M 100.00% | $9.12M |
| 2023-03-31 | Not split by product $8.88M 100.00% | $8.88M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |